Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report
Introduction. Anti-tumor necrosis factor α (anti-TNF-α) antibodies are used to treat immune-mediated inflammatory diseases (IMID), which include inflammatory bowel diseases or psoriasis. In the group of adverse events induced by anti-TNF agents we can observe psoriatic lesions. Case report . We...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2015-09-01
|
| Series: | Przegląd Dermatologiczny |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Adalimumab-induced-psoriasis-during-the-treatment-of-inflammatory-bowel-disease-case-report,56,25611,1,1.html |
| _version_ | 1811333522190761984 |
|---|---|
| author | Edyta Lelonek Magdalena Dębicka Joanna Maj Anita Hryncewicz-Gwóźdź Łukasz Matusiak |
| author_facet | Edyta Lelonek Magdalena Dębicka Joanna Maj Anita Hryncewicz-Gwóźdź Łukasz Matusiak |
| author_sort | Edyta Lelonek |
| collection | DOAJ |
| description | Introduction. Anti-tumor necrosis factor α (anti-TNF-α) antibodies are used to treat immune-mediated inflammatory diseases (IMID), which include inflammatory bowel diseases or psoriasis. In the group of adverse events induced by anti-TNF agents we can observe psoriatic lesions.
Case report . We present two women who in the course of therapy of Crohn's disease with adalimumab (ADA) developed psoriasis. Diagnosis was based on the clinical picture and confirmed by histopathological examination. In the first case, treatment with ADA was continued and topical therapy was started, with a good effect. The second patient abandoned ADA therapy and the skin lesions resolved due to the external treatment, too.
Conclusions . The comorbidity of IMID creates therapeutic difficulties and requires further study to elucidate pathophysiology of these diseases, as well as to clarify the mechanism of action of anti-TNF agents. |
| first_indexed | 2024-04-13T16:52:55Z |
| format | Article |
| id | doaj.art-5455238d0e694826a90e007a76da15c2 |
| institution | Directory Open Access Journal |
| issn | 0033-2526 2084-9893 |
| language | English |
| last_indexed | 2024-04-13T16:52:55Z |
| publishDate | 2015-09-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Przegląd Dermatologiczny |
| spelling | doaj.art-5455238d0e694826a90e007a76da15c22022-12-22T02:38:53ZengTermedia Publishing HousePrzegląd Dermatologiczny0033-25262084-98932015-09-01102433133510.5114/dr.2015.5342225611Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case reportEdyta LelonekMagdalena DębickaJoanna MajAnita Hryncewicz-GwóźdźŁukasz MatusiakIntroduction. Anti-tumor necrosis factor α (anti-TNF-α) antibodies are used to treat immune-mediated inflammatory diseases (IMID), which include inflammatory bowel diseases or psoriasis. In the group of adverse events induced by anti-TNF agents we can observe psoriatic lesions. Case report . We present two women who in the course of therapy of Crohn's disease with adalimumab (ADA) developed psoriasis. Diagnosis was based on the clinical picture and confirmed by histopathological examination. In the first case, treatment with ADA was continued and topical therapy was started, with a good effect. The second patient abandoned ADA therapy and the skin lesions resolved due to the external treatment, too. Conclusions . The comorbidity of IMID creates therapeutic difficulties and requires further study to elucidate pathophysiology of these diseases, as well as to clarify the mechanism of action of anti-TNF agents.http://www.termedia.pl/Adalimumab-induced-psoriasis-during-the-treatment-of-inflammatory-bowel-disease-case-report,56,25611,1,1.htmlpsoriasis anti-TNF agents adalimumab Crohn’s disease |
| spellingShingle | Edyta Lelonek Magdalena Dębicka Joanna Maj Anita Hryncewicz-Gwóźdź Łukasz Matusiak Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report Przegląd Dermatologiczny psoriasis anti-TNF agents adalimumab Crohn’s disease |
| title | Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report |
| title_full | Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report |
| title_fullStr | Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report |
| title_full_unstemmed | Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report |
| title_short | Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report |
| title_sort | adalimumab induced psoriasis during the treatment of inflammatory bowel disease case report |
| topic | psoriasis anti-TNF agents adalimumab Crohn’s disease |
| url | http://www.termedia.pl/Adalimumab-induced-psoriasis-during-the-treatment-of-inflammatory-bowel-disease-case-report,56,25611,1,1.html |
| work_keys_str_mv | AT edytalelonek adalimumabinducedpsoriasisduringthetreatmentofinflammatoryboweldiseasecasereport AT magdalenadebicka adalimumabinducedpsoriasisduringthetreatmentofinflammatoryboweldiseasecasereport AT joannamaj adalimumabinducedpsoriasisduringthetreatmentofinflammatoryboweldiseasecasereport AT anitahryncewiczgwozdz adalimumabinducedpsoriasisduringthetreatmentofinflammatoryboweldiseasecasereport AT łukaszmatusiak adalimumabinducedpsoriasisduringthetreatmentofinflammatoryboweldiseasecasereport |